ERBB2 and triple-negative breast carcinoma: Of the patients with available targeted sequencing, 64.4% (N = 515) had hormone receptor positive (HR + ) HER2 negative (HER2-, lack of HER2 over-expression and/or gene amplification) disease, 9.1% (N = 72) were HER2 positive, and 17.3% (N = 138) had triple-negative breast cancer (TNBC, Supplementary Table 1).